Advertisement

Hematology and Oncology

Home Hematology and Oncology
Voluntarily stopping eating and drinking is a course that patients may choose to hasten their death

Legal Aspects to Consider in Voluntary Refusal to Eat, Drink

Patients, families, clinicians must consider clinical, ethical, legal aspects of VSED to hasten death

Model Using Routine Clinical Data May Predict Pancreatic Cancer Risk

Findings show promise following diagnosis of impaired fasting glucose

The duration of disease-free survival is increased with sunitinib treatment for patients with locoregional

Renal-Cell Cancer Disease-Free Survival Up With Sunitinib

Findings in patients with locoregional, high-risk clear-cell renal-cell carcinoma
The World Health Organization's pain care guidelines contain false claims about the safety of prescription opioid painkillers and should be withdrawn

U.S. Lawmakers Say WHO Opioid Guidelines Too Lax

Organization claims guidelines influenced by people with financial ties to Purdue Pharma
Westernization of the diet induces changes in biomarkers of colon cancer risk within two weeks

Colon Cancer Risk Markers Appear Within Two Weeks of Diet Change

More polyps, other markers of colon tumor risk in those eating 'Western' high-fat, low-fiber fare
Physicians are aware of patients' difficulty with affording medical care and consider out-of-pocket costs in their decision making

Doctors Aware of Patient Difficulties Affording Medical Care

Three-quarters of doctors surveyed say they consider out-of-pocket costs when making clinical decisions
There is an urgent need for coordinated

Coordinated Care Needed for Cancer Survivors, Caregivers

Efforts needed in implementing routine assessments of needs, facilitating personalized referrals
Higher HER3 expression is associated with improved survival with the addition of panitumumab treatment for patients with RAS wild-type advanced colorectal cancer

HER3 Linked to Improved Survival With Panitumumab

Addition of panitumumab to irinotecan tied to improved survival in RAS wt advanced colorectal CA
Anti-programmed cell death-1 therapy for metastatic melanoma is associated with the development of immune-related cutaneous events

Melanoma Therapy Tied to Cutaneous Adverse Events

Anti-programmed cell death-1 therapy tied to lichenoid reactions, eczema, vitiligo